• Drinks bottler turns production to hand sanitiser in glass bottles from Ardagh Group

    Ardagh Group in Dongen, Netherlands has supplied Belgium-based drinks packager, Konings, for 25 years with glass bottles for well-known beverage brands across Europe. As suppliers to the essential food and beverage industry, both companies have continued to work during Covid-19, to ensure supplies continue to reach retail shelves. In response to the shortage of supply during the Covid-19 pandemic, Konings converted one production line to filling hand sanitiser in Ardagh’s 500ml bottles, for the health sector.

  • Why You Need Sanitizer Packaging?

    Brands and business should realize as quickly as possible that the ruling authority is in the customer’s hand. You know the amount of effort, ideas, vision, hard word, creativity, innovation and thoughts that you try to put into a product as a business entity. You do all of that just to let the customers decide its fate at the end of the day. Ultimately, it’s the buyer that is going to decide if you a product that is worthy of their purchase. They will decide if they feel like investing in your business or not. The customers will never ever know about the tiring journey, the efforts, hard word, the trails that simply went into the whole designing and manufacturing of your product. On the other hand, for the customer it’s only a matter of few seconds for it to decide if your product has what it takes, if it is meeting its demands and standards. Therefore, it would be best for you to not give them any reason to reject your product. For this, you need to have the perfect packaging for your product. You need to have an ideally beautiful Sanitizer Packaging choice for your product that can hit the market by the storm.

    You Need To Work on Your Customization

    Brand manufacturers know they are up against a tight competition in the market because it’s full of variations of the same goods. These variations further make it hard for the buyers to make any decision because they are in a fix. They do not know which brand to choose. They definitely know the product they want to buy, but it all comes down to the brand they will go after. Because there are numerous number of brands that offer more or less similar goods in the market. The only thing, one product may be slightly better than the other one. This is the reason why making a sound call for the customers is not an easy thing. Manufacturers first need to try hard as possible to attract the customers to their products. Only after they have done that successfully will the customers be able to decide than the one they are about to opt for is good for them – yours in other words. Given this reason, the customized choices are simply mandate in such instances. But in saying that, ever wonder why this reason? Well, we are here to explain everything to you. Let us tell you why we consider this particular one element has the tendency to give your goods the needed nudge that can simply take your products to the next level. When you have these choices wrapped around your product, they simply add a hint of innovation, creativity, and uniqueness to the goods; products that otherwise could be simply basic things. Or in other words, these would be more or less the exact same of similar nature as the all the rest in the market that customers might come across. In order to gain the customer’s attention and simply hold it, manufacturers need to employ all these methods and techniques that are a cinch to win them the needed customer base. Manufacturers need to understand the psychology of buying. They need to know that this is perhaps a psychological game that they need to play with the buyers and master it at the same time. In the current world, most of the manufacturers are in constant search of diversified needs and preferences of the buyers. Only by knowing these needs and preferences will the manufacturers be able to cater to the varied options and choices of the customers. Considering this very factor in mind, it seems as if the customized choices are perhaps the most efficient consumption of all the available resources. The best part, there is a minimum chance of depletion in this regard.

    Customization with Its Various Benefits

    You need to realize as a manufacturer that customization of packaging choices have unique benefits of its own. You get to promote your business with the help of these choices, and that too quite efficiently and effectively. At the same time, you are giving the customers an easy reason to identity you. They will easily know yours is the product they need and will have the peace of mind that they are buying from you. However, just as the buyers need to make a selection from all the brands and/or products from all those countless simply scattered all in front of them, the brands on the other hand to go through the same dilemma when they need to select a Kraft option that is going to represent your business and manufactured goods. The brands too need to face that horrid and dreaded decision making factor. They need to ensure they are making the right selection and choice. They need to be accurate in every decision that they make from selecting the right material for packaging, the colors, shape, the packaging size, style, and design to the printing options being the best in line. These are all the selections they need to make. It can all be a little too complicated for them. However, when this decision is made accurately, you need to trust us on this one, this final word will never be regretted. A packaging company will definitely have its limits and creativity tested when it’s about designing the choices. However, they are experts in them and they know how to sort out the best Custom Packaging solutions that can be available in the market for the packaging process. These companies have the means and technology that will allow them to achieve targets quite easily and do the unthinkable. Having said that, the only thing that needs to be done accurately is selecting the best choices out of a numerous. This is for their own good at the end.

  • Temperature and tampering technology for COVID-19 drugs

    As the world’s scientists rush to find vaccines and therapeutics to treat COVID-19, there’s another group of scientists who are working just as hard to protect the drugs and safely deliver them to patients and - - in addition - - fight counterfeiters, the companies explain. “Once a COVID-19 vaccine is produced, it needs to be safely distributed throughout the world and must survive the risks of freezing, heat abuse, sun (UV) damage, tampering and counterfeiting.” said Lyle Small, CTI’s CEO. “The world is throwing money at beating the coronavirus in a compressed timeline. This just amplifies the risk but CTI has simple solutions for all of these related efficacy challenges,” he added. According to the World Health Organization, seven of the 10 top-selling drugs in the world are damaged by freezing temperatures, including vaccines for influenza and pneumonia. “ATI is already working with dozens of pharmaceutical companies and we are diligently launching this program to support all of their COVID-19 R&D and launch efforts,” said Randall Lane, CEO of ATI. CTI and ATI’s goals are to protect at least 100 million units of drugs being distributed to health care officials. The CTI donation has an equivalent value of US$5 million. Pharmaceutical companies can request samples or place orders via CTI Inks. CTI claims to be the world’s largest supplier of smart, specialty, colour-changing technology that responds to temperature, light and pressure, exporting to 55 countries. American Thermal Instruments produces custom temperature monitoring solutions for industries that require accurate and measurable systems including pharmaceutical, medical, food, beverage and industrial sectors.
  • Aptar Pharma’s PureHale™ Respiratory Device Launches with Blairex Laboratories’ Breathe Free® Essentials Brand

    This marks the first commercial launch worldwide of a brand using Aptar Pharma’s innovative PureHale™ respiratory technology. Breathe Free® Essentials is formulated with moisturizing saline and 100% natural essential oils, and is available in three blends – Soothing, Relaxing and Clarity. Each Breathe Free® Essentials kit comes with a personal face mask and adapter for effortless, on-the-go delivery for today’s in-demand lifestyle. Aptar Pharma’s PureHale™ is a portable and ready-to-use delivery solution designed for upper respiratory care. An alternative to traditional nebulizer technology, PureHale™, when used with saline and other natural ingredients, distributes a fine, gentle mist to cleanse, moisturize and soothe the upper respiratory tract, in turn helping to reduce any irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues. PureHale’s user-friendly system is based on Aptar Pharma’s well-established Bag-on-Valve technology which, when actuated, delivers a continuous mist with fine particles of approximately 20µm optimized for targeted deposition to the upper airways. Unlike traditional nebulizers, the PureHale™ system does not require batteries or the prefilling of a reservoir. Both quiet and lightweight, the device can be used with or without a mask, offering adaptable treatment options. Jeffrey Logston, President, Blairex Laboratories, Inc., “Blairex Laboratories has a history of offering products in innovative packaging and delivery systems. Breathe Free® Essentials continues that legacy. We designed Breathe Free® Essentials to create an on-the-go personal retreat, and hope to provide our customers with a much needed moment to breathe.” “We are pleased to partner with Blairex on this first launch of our PureHale™ device with Breathe Free® Essentials,” commented Gael Touya, President of Aptar Pharma. “PureHale’s innovative technology is meeting a new need in the marketplace for portable, on-the-go respiratory support. We look forward to this and future launches using PureHale™.”
  • EU actions to support availability of medicines during COVID-19 pandemic – update #7

    The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a virtual meeting on 3 June 2020. Regular participation in the meeting of the steering group was extended to all the heads of the national competent authorities (NCAs) of the EU Member States to discuss the measures taken by EU authorities to ensure the continued availability of medicines in Europe during the ongoing COVID-19 pandemic.
  • Abrasion-Resistant and Award-Winning: TEVA Relies on Schreiner MediPharm for Novel Adrenaline Injector Label

    Oberschleissheim, June 8, 2020 – Patients suffering from life-threatening allergies always carry a life-saving companion with them: an adrenaline autoinjector in order to immediately inject themselves in the event of an anaphylactic shock and to thus counter an allergic reaction.

  • LC Packaging COVID-19 Update

    we would like to further inform our customers about how we are securing our supplies and services and what precautions we have taken and will continue to take to ensure the health and wellbeing of you and our colleagues. LC Packaging is taking the situation very seriously and we are following all measures recommended by the authorities in the countries where we are present.

  • Messe Frankfurt to focus on highlighting strong anti-counterfeiting measures in wake of Covid-19

    As demand for medical supplies soars worldwide in the fight against Covid-19, there is a parallel risk of substandard and counterfeit medicines in the global market. With India being one of the world's largest producers of medical supplies, there is an urgent need to bring in strong anti-counterfeiting measures which will be addressed at Messe Frankfurt’s upcoming conference - Pharmasafe India 2020.

  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020

    The Committee recommended granting a marketing authorisation for a new vaccine that provides active immunisation to prevent Ebola virus disease in individuals aged one year and older. The new Ebola vaccine consists of two components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster. Zabdeno and Mvabea were evaluated under EMA's accelerated assessment mechanism, a tool which aims to speed up patients' access to new medicines if there is an unmet medical need. For more information, see the press release in the grid below. The CHMP recommended granting a marketing authorisation for Hepcludex* (bulevirtide), for the treatment of chronic hepatitis delta virus infection in adult patients with compensated liver disease. Because there are no treatments currently approved for hepatitis D, Hepcludex benefited from the support of the PRIME scheme, EMA’s platform for early and enhanced dialogue with developers of promising new medicines that address unmet medical needs. Piqray (alpelisib) received a positive opinion from the CHMP for the treatment of locally advanced or metastatic breast cancer with a PIK3CA mutation. The CHMP recommended granting a conditional marketing authorisation for Rozlytrek (entrectinib), for the treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion, or patients with ROS1-positive advanced non-small cell lung cancer. Xenleta (lefamulin) received a positive opinion for the treatment of community-acquired pneumonia in adults. The biosimilar medicine Zercepac (trastuzumab) received a positive opinion for the treatment of breast and gastric cancer. The generic medicine Apixaban Accord (apixaban) received a positive opinion for the treatment and prevention of venous thromboembolic events in adult patients and for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Five recommendations on extensions of therapeutic indication The Committee recommended extensions of indication for Invokana, Lynparza, Ofev, Sivextro and Taltz. Update on remdesivir The CHMP discussed the status of the review of remdesivir for treating patients with COVID-19. On 30 April 2020, the CHMP started a rolling review of data and the first cycle of this rolling review was concluded on 15 May; the CHMP requested some further data and agreed that the next step would be for the company to submit this data together with an application for a conditional marketing authorisation. The company has not yet submitted an application but it is expected to do so shortly. Once an application has been submitted, the Committee will assess it under a timeline which will be reduced to the absolute minimum to still allow for a thorough evaluation of benefits and risks, meaning an opinion could come soon depending on the robustness of the data submitted. Withdrawals of applications Applications for initial marketing authorisations for Erlotinib Accord (erlotinib) and Fingolimod Mylan (fingolimod) have been withdrawn. Erlotinib Accord was intended for the treatment of non-small-cell lung cancer and pancreatic cancer. Fingolimod Mylan was intended for the treatment of multiple sclerosis. Question-and-answer documents on these withdrawals are available in the grid below. Agenda and minutes The agenda of the May meeting is published on EMA's website. Minutes of the April 2020 CHMP meeting will be published in the coming weeks. CHMP statistics Key figures from the May 2020 CHMP meeting are represented in the graphic below. * This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products (COMP) at the time of approval to determine whether the information available to date allows maintaining the medicine's orphan status and granting the medicine ten years of market exclusivity.

  • New vaccine for prevention of Ebola virus disease recommended for approval in the European Union

    EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for a new Ebola vaccine that provides active immunisation to prevent Ebola virus disease (Zaire ebolavirus species) in individuals aged 1 year and older.
  • Pages